单细胞追踪揭示黑色素瘤 TIL 治疗过程中肿瘤反应性 T 细胞的可塑性
Single-cell tracking reveals tumor-reactive T cell plasticity during melanoma TIL therapy.
TIL(肿瘤浸润淋巴细胞)过继细胞治疗可在转移性黑色素瘤中诱导持久缓解,然而在体外扩增过程中及回输后,调控肿瘤反应性T细胞命运的克隆和转录动态仍知之甚少。
英文原题:Single-cell profiling of acral melanoma infiltrating lymphocytes reveals a suppressive tumor microenvironment.
我们的研究为提高ALM免疫治疗的疗效提供了基础。
肢端黑素瘤(ALM)是非高加索人群中最常见的黑素瘤亚型。尽管癌症免疫治疗取得了进展,但目前的免疫检查点抑制剂对ALM仍不理想。因此,我们通过对ALM中肿瘤浸润T淋巴细胞(TILs)的T细胞受体进行反应性筛选,并结合单细胞表型分析,开展了全面的免疫图谱分析。与皮肤黑素瘤相比,ALM显示出肿瘤反应性CD8细胞簇频率较低,并富集具有直接肿瘤识别能力的调节性T细胞,提示ALM中存在抑制性免疫微环境。肿瘤反应性CD8 TILs在具有治疗意义的亚群中表现出共抑制分子的异质性表达,包括KLRC1(NKG2A)。总体而言,我们的研究为提高ALM免疫治疗疗效提供了基础。
Acral lentiginous melanoma (ALM) is the most common melanoma subtype in non-Caucasians. Despite advances in cancer immunotherapy, current immune checkpoint inhibitors remain unsatisfactory for ALM. Hence, we conducted comprehensive immune profiling using single-cell phenotyping with reactivity screening of the T cell receptors of tumor-infiltrating T lymphocytes (TILs) in ALM. Compared with cutaneous melanoma, ALM showed a lower frequency of tumor-reactive CD8 clusters and an enrichment of regulatory T cells with direct tumor recognition ability, suggesting a suppressive immune microenvironment in ALM. Tumor-reactive CD8 TILs showed heterogeneous expression of coinhibitory molecules, including KLRC1 (NKG2A), in subpopulations with therapeutic implications. Overall, our study provides a foundation for enhancing the efficacy of immunotherapy in ALM.
MEMBER ACCOUNT
登录成功会直接打开下一页。